Literature DB >> 31034363

Alemtuzumab to be restricted pending review, says EMA.

Becky McCall.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31034363     DOI： 10.1016/S0140-6736(19)30935-3

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

1.  Alemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunity.

Authors:  Tobias Ruck; Sumanta Barman; Andreas Schulte-Mecklenbeck; Steffen Pfeuffer; Falk Steffen; Christopher Nelke; Christina B Schroeter; Alice Willison; Michael Heming; Thomas Müntefering; Nico Melzer; Julia Krämer; Maren Lindner; Marianne Riepenhausen; Catharina C Gross; Luisa Klotz; Stefan Bittner; Paolo A Muraro; Tilman Schneider-Hohendorf; Nicholas Schwab; Gerd Meyer Zu Hörste; Norbert Goebels; Sven G Meuth; Heinz Wiendl
Journal:  Brain       Date:  2022-06-03       Impact factor: 15.255

2.  Cornuside alleviates experimental autoimmune encephalomyelitis by inhibiting Th17 cell infiltration into the central nervous system.

Authors:  Rongbo Zhang; Jin Liu; Bin Xu; You Wu; Shunli Liang; Qiang Yuan
Journal:  J Zhejiang Univ Sci B       Date:  2021-05-15       Impact factor: 3.066

Review 3.  The Meaning of Immune Reconstitution after Alemtuzumab Therapy in Multiple Sclerosis.

Authors:  Simona Rolla; Alessandro Maglione; Stefania Federica De Mercanti; Marinella Clerico
Journal:  Cells       Date:  2020-06-03       Impact factor: 6.600

4.  Signatures of immune reprogramming in anti-CD52 therapy of MS: markers for risk stratification and treatment response.

Authors:  Laura Bierhansl; Tobias Ruck; Steffen Pfeuffer; Catharina C Gross; Heinz Wiendl; Sven G Meuth
Journal:  Neurol Res Pract       Date:  2019-12-13

5.  Implications of extreme serum neurofilament light chain levels for the management of patients with relapsing multiple sclerosis.

Authors:  Sinah Engel; Maria Protopapa; Falk Steffen; Vakis Papanastasiou; Christoforos Nicolaou; Michalis Protopapas; Frauke Zipp; Stefan Bittner; Felix Luessi
Journal:  Ther Adv Neurol Disord       Date:  2021-04-20       Impact factor: 6.570
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.